Aβ inhibits the proteasome and enhances amyloid and tau accumulation

Neurobiology of Aging

Volumn 29, Issue 11, 2008, Pages 1607-1618

  Tseng, Bertrand P ^a   Green, Kim N ^a   Chan, Julie L ^a   Blurton Jones, Mathew ^a   LaFerla, Frank M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Immunotherapy; Oliogmers; Proteasome; Tau; Transgenic

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; EPOXOMICIN; PROTEASOME; PROTEASOME INHIBITOR; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FOLDING; AGING; ANIMAL; BRAIN; CELL FREE SYSTEM; METABOLISM;

AGING; AMYLOID; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; CELL-FREE SYSTEM; FEMALE; MALE; MICE; PROTEASOME ENDOPEPTIDASE COMPLEX; TAU PROTEINS;

EID: 51449096696     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.04.014     Document Type: Article

References (39)

1. Adori C., Kovacs G.G., Low P., Molnar K., Gorbea C., Fellinger E., Budka H., Mayer R.J., and Laszlo L. The ubiquitin-proteasome system in Creutzfeldt-Jakob and Alzheimer disease: intracellular redistribution of components correlates with neuronal vulnerability. Neurobiol. Dis. 19 3 (2005) 427-435
2. Almeida C.G., Takahashi R.H., and Gouras G.K. Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J. Neurosci. 26 16 (2006) 4277-4288
3. Bertram L., Hiltunen M., Parkinson M., Ingelsson M., Lange C., Ramasamy K., Mullin K., Menon R., Sampson A.J., Hsiao M.Y., Elliott K.J., Velicelebi G., Moscarillo T., Hyman B.T., Wagner S.L., Becker K.D., Blacker D., and Tanzi R.E. Family-based association between Alzheimer's disease and variants in UBQLN1. N. Engl. J. Med. 352 9 (2005) 884-894
4. Billings L.M., Oddo S., Green K.N., McGaugh J.L., and Laferla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45 5 (2005) 675-688
5. Cardozo C., and Michaud C. Proteasome-mediated degradation of tau proteins occurs independently of the chymotrypsin-like activity by a nonprocessive pathway. Arch. Biochem. Biophys. 408 1 (2002) 103-110
6. David D.C., Layfield R., Serpell L., Narain Y., Goedert M., and Spillantini M.G. Proteasomal degradation of tau protein. J. Neurochem. 83 1 (2002) 176-185
7. de Pril R., Fischer D.F., Maat-Schieman M.L., Hobo B., de Vos R.A., Brunt E.R., Hol E.M., Roos R.A., and van Leeuwen F.W. Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. Hum. Mol. Genet. 13 16 (2004) 1803-1813
8. Farris W., Mansourian S., Leissring M.A., Eckman E.A., Bertram L., Eckman C.B., Tanzi R.E., and Selkoe D.J. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am. J. Pathol. 164 4 (2004) 1425-1434
9. Feuillette S., Blard O., Lecourtois M., Frebourg T., Campion D., and Dumanchin C. Tau is not normally degraded by the proteasome. J. Neurosci. Res. 80 3 (2005) 400-405
10. Gong B., Cao Z., Zheng P., Vitolo O.V., Liu S., Staniszewski A., Moolman D., Zhang H., Shelanski M., and Arancio O. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 126 4 (2006) 775-788
11. Gregori L., Fuchs C., Figueiredo-Pereira M.E., Van Nostrand W.E., and Goldgaber D. Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J. Biol. Chem. 270 34 (1995) 19702-19708
12. Hama E., Shirotani K., Masumoto H., Sekine-Aizawa Y., Aizawa H., and Saido T.C. Clearance of extracellular and cell-associated amyloid beta peptide through viral expression of neprilysin in primary neurons. J. Biochem. (Tokyo) 130 6 (2001) 721-726
13. Hoyt M.A., Zhang M., and Coffino P. Ubiquitin-independent mechanisms of mouse ornithine decarboxylase degradation are conserved between mammalian and fungal cells. J. Biol. Chem. 278 14 (2003) 12135-12143
14. Keller J.N., Hanni K.B., and Markesbery W.R. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75 1 (2000) 436-439
15. Khare S.D., Ding F., Gwanmesia K.N., and Dokholyan N.V. Molecular origin of polyglutamine aggregation in neurodegenerative diseases. PLoS Comput. Biol. 1 3 (2005) 230-235
16. Klein W.L., Stine Jr. W.B., and Teplow D.B. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging 25 5 (2004) 569-580
17. Layfield R., Lowe J., and Bedford L. The ubiquitin-proteasome system and neurodegenerative disorders. Essays Biochem. 41 (2005) 157-171
18. Lindersson E., Beedholm R., Hojrup P., Moos T., Gai W., Hendil K.B., and Jensen P.H. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J. Biol. Chem. 279 13 (2004) 12924-12934
19. Lopez Salon M., Pasquini L., Besio Moreno M., Pasquini J.M., and Soto E. Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. Exp. Neurol. 180 2 (2003) 131-143
20. Murata S., Chiba T., and Tanaka K. CHIP: a quality-control E3 ligase collaborating with molecular chaperones. Int. J. Biochem. Cell Biol. 35 5 (2003) 572-578
21. Murata S., Minami Y., Minami M., Chiba T., and Tanaka K. CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep. 2 12 (2001) 1133-1138
22. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., and LaFerla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43 3 (2004) 321-332
23. Oddo S., Caccamo A., Green K.N., Liang K., Tran L., Chen Y., Leslie F.M., and LaFerla F.M. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 102 8 (2005) 3046-3051
24. Oddo S., Caccamo A., Kitazawa M., Tseng B.P., and LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 24 8 (2003) 1063-1070
25. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., and LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39 3 (2003) 409-421
26. Oddo S., Caccamo A., Smith I.F., Green K.N., and Laferla F.M. A Dynamic Relationship between Intracellular and Extracellular Pools of A{beta}. Am. J. Pathol. 168 1 (2006) 184-194
27. Oddo S., Caccamo A., Tran L., Lambert M.P., Glabe C.G., Klein W.L., and Laferla F.M. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease: a link between Abeta and tau pathology. J. Biol. Chem. 281 3 (2006) 1599-1604
28. Oh S., Hong H.S., Hwang E., Sim H.J., Lee W., Shin S.J., and Mook-Jung I. Amyloid peptide attenuates the proteasome activity in neuronal cells. Mech. Ageing Dev. 126 12 (2005) 1292-1299
29. Park Y., Hong S., Kim S.J., and Kang S. Proteasome function is inhibited by polyglutamine-expanded ataxin-1, the SCA1 gene product. Mol. Cells 19 1 (2005) 23-30
30. Petrucelli L., Dickson D., Kehoe K., Taylor J., Snyder H., Grover A., De Lucia M., McGowan E., Lewis J., Prihar G., Kim J., Dillmann W.H., Browne S.E., Hall A., Voellmy R., Tsuboi Y., Dawson T.M., Wolozin B., Hardy J., and Hutton M. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13 7 (2004) 703-714
31. Ross C.A., and Pickart C.M. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol. 14 12 (2004) 703-711
32. Sahara N., Murayama M., Mizoroki T., Urushitani M., Imai Y., Takahashi R., Murata S., Tanaka K., and Takashima A. In vivo evidence of CHIP up-regulation attenuating tau aggregation. J. Neurochem. 94 5 (2005) 1254-1263
33. Shirotani K., Tsubuki S., Iwata N., Takaki Y., Harigaya W., Maruyama K., Kiryu-Seo S., Kiyama H., Iwata H., Tomita T., Iwatsubo T., and Saido T.C. Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J. Biol. Chem. 276 24 (2001) 21895-21901
34. Song S., Kim S.Y., Hong Y.M., Jo D.G., Lee J.Y., Shim S.M., Chung C.W., Seo S.J., Yoo Y.J., Koh J.Y., Lee M.C., Yates A.J., Ichijo H., and Jung Y.K. Essential role of E2-25K/Hip-2 in mediating amyloid-beta neurotoxicity. Mol. Cell 12 3 (2003) 553-563
35. Takahashi R.H., Almeida C.G., Kearney P.F., Yu F., Lin M.T., Milner T.A., and Gouras G.K. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24 14 (2004) 3592-3599
36. van Leeuwen F.W., de Kleijn D.P., van den Hurk H.H., Neubauer A., Sonnemans M.A., Sluijs J.A., Koycu S., Ramdjielal R.D., Salehi A., Martens G.J., Grosveld F.G., Peter J., Burbach H., and Hol E.M. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science (New York, NY) 279 5348 (1998) 242-247
37. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 6880 (2002) 535-539
38. Walsh D.M., Klyubin I., Fadeeva J.V., Rowan M.J., and Selkoe D.J. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30 4 (2002) 552-557
39. Walsh D.M., and Selkoe D.J. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett. 11 3 (2004) 213-228